HUP9904500A3 - Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia - Google Patents

Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Info

Publication number
HUP9904500A3
HUP9904500A3 HU9904500A HUP9904500A HUP9904500A3 HU P9904500 A3 HUP9904500 A3 HU P9904500A3 HU 9904500 A HU9904500 A HU 9904500A HU P9904500 A HUP9904500 A HU P9904500A HU P9904500 A3 HUP9904500 A3 HU P9904500A3
Authority
HU
Hungary
Prior art keywords
bicistron
dyslipoproteinemia
adenovirus
recombinant
pathological conditions
Prior art date
Application number
HU9904500A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of HUP9904500A2 publication Critical patent/HUP9904500A2/hu
Publication of HUP9904500A3 publication Critical patent/HUP9904500A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9904500A 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia HUP9904500A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (2)

Publication Number Publication Date
HUP9904500A2 HUP9904500A2 (hu) 2000-05-28
HUP9904500A3 true HUP9904500A3 (en) 2002-01-28

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904500A HUP9904500A3 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Country Status (14)

Country Link
EP (1) EP0941355A1 (fr)
JP (1) JP2001506488A (fr)
KR (1) KR20000053320A (fr)
AU (1) AU721654B2 (fr)
BR (1) BR9712957A (fr)
CA (1) CA2271437A1 (fr)
CZ (1) CZ170399A3 (fr)
FR (1) FR2755975B1 (fr)
HU (1) HUP9904500A3 (fr)
IL (1) IL129823A0 (fr)
NO (1) NO992260D0 (fr)
SK (1) SK63499A3 (fr)
WO (1) WO1998022606A1 (fr)
ZA (1) ZA9710271B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506651A (ja) * 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
AU7769800A (en) * 1999-08-10 2001-03-05 Develogen Ag Fur Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
WO2001073093A2 (fr) * 2000-03-24 2001-10-04 Cell Genesys, Inc. Vecteurs adenoviraux a specificite cellulaire comprenant un site recepteur interne du ribosome
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7208322B2 (en) 2001-04-02 2007-04-24 Agilent Technologies, Inc. Sensor surfaces for detecting analytes
CA2843556A1 (fr) * 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Procede de test de dissolution de compositions solides contenant des enzymes digestives
JP7316711B2 (ja) 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド 脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213779T1 (de) * 1991-08-07 2002-03-15 W French Anderson Interne ribosom eintrittsstellen enthaltene retrovirale vektoren
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
CA2271437A1 (fr) 1998-05-28
NO992260L (no) 1999-05-10
ZA9710271B (en) 1998-08-21
WO1998022606A1 (fr) 1998-05-28
KR20000053320A (ko) 2000-08-25
SK63499A3 (en) 2000-05-16
AU5125298A (en) 1998-06-10
IL129823A0 (en) 2000-02-29
CZ170399A3 (cs) 1999-08-11
BR9712957A (pt) 2000-02-01
FR2755975B1 (fr) 1999-05-07
JP2001506488A (ja) 2001-05-22
FR2755975A1 (fr) 1998-05-22
NO992260D0 (no) 1999-05-10
EP0941355A1 (fr) 1999-09-15
HUP9904500A2 (hu) 2000-05-28
AU721654B2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
HUP0001271A3 (en) Method for purifying recombinant adenovirus
GB2332606B (en) Secure boot
GB9627089D0 (en) Microcomputer
IL127682A0 (en) Antiballistic shaped part
PL337130A1 (en) Alternatively oriented adenovirus
AP2002002661A0 (en) Combination therapy for oesteoporosis
IL127455A0 (en) Progesterone for treating or reducing ischemia
IL115582A0 (en) Methods for treating resistant tumors
PL332940A1 (en) Refractory assemblies
IL129823A0 (en) Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
GB0127669D0 (en) Polypeptide
IL140743A0 (en) Recombinant herpes viruses for preparing recombinant adeno-associated viruses
GB9626130D0 (en) Improved doctor assembly
PL313911A1 (en) Theraputic lamp
GB9609908D0 (en) Overflow arrangement
GB9615393D0 (en) Gate
EP0880468A4 (fr) Traitement de la bauxite
SG52991A1 (en) Formlock shoes with flats
TW372483U (en) Light penetrative grinding system
HU0500413D0 (en) Process for purifying recombinant adenovirus
HU989U (en) Border fastening for tilt
PL321036A1 (en) Gate system
GB9418821D0 (en) Ovulation predictor
GB9819387D0 (en) Polypeptide
HU9600619D0 (en) Treatment with onion-oil